Day One Biopharmaceuticals Inc (DAWN) Price

Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 184 full-time employees. The company went IPO on 2021-05-27. The firm partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.